抗肿瘤抗生素的研究进展
被引量：4
The progress of anti-tumor antibiotic
摘要
具有抗肿瘤活性的抗生素称之为抗肿瘤抗生素,根据结构不同可以分为烯二炔类、糖肽类、蒽环类、大环内脂类、苯并二吡咯类及喹喔啉类等。本文对抗肿瘤抗生素的活性及作用机制等进行了综述,并初步展望了其未来研究方向。
出处
《中国生化药物杂志》
CAS
CSCD
北大核心
2012年第4期498-501,共4页
Chinese Journal of Biochemical Pharmaceutics
参考文献30
-
1Galm U ,Wendt-Pienkowski E ,Wang L,et al. Comparative analysis of the biosynthetic gene clusters and pathways for three structurally related antitumor antibiotics : bleomycin, tallysomycin, and zorbamycin[J]. J Nat Prod,2011,74(3) :526-536.
-
2Chen Y,Yin M,Horsman G P,et al. Improvement of the enediyne antitumor antibiotic C-1027 production by manipulating its biosynthetic pathway regulation in Streptomyces globisporus [ J]. J Nat Prod,20l 1,74(3 ) :420424.
-
3Usui N, Takeshita A, Nakaseko C, et al. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML):Japan adult leukemia study group (JALSG) -AML206 study [ J ]. Cancer Sci, 2011,102(7) :1358-1365.
-
4DiJoseph J F, Dougher M M, Evans D Y, et al. Preclinical antitumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of ealicheamicin,compared with non-targeted combination chemotherapy with CVP or CHOP[ J]. Cancer Chemother Pharmacol,2011, 67(4) :741-749.
-
5Ogura M,Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544)in Japanese patients with follicular Iymphoma pretreated with rituximab-based therapy [ J ]. Cancer Sci, 2010,101 (8) :1840-1845.
-
6王风强,尚伯杨,甄永苏.抗IV型胶原酶单抗3G11与力达霉素偶联物的抗肿瘤作用[J].药学学报,2003,38(7):515-519. 被引量：11
-
7Gao N, Shang B, Zhang X, et al. Potent antitumor actions of the new antibiotic boningmycin through indaction of apoptosis and cellular senescence[J]. Anticancer Drugs,2011,22(2) :166-175.
-
8张宏印,谢忠,李电东.博安霉素抗人肝癌的作用及其作用机制的研究[J].中国新药杂志,2001,10(10):749-752. 被引量：3
-
9张宏印,谢忠,李宗铠,李电东.博安霉素抗人结肠癌作用的研究[J].中国抗生素杂志,2002,27(1):55-58. 被引量：3
-
10陆晓晶.化学类抗肿瘤药物的研究进展[J].浙江化工,2010,41(7):8-11. 被引量：8
二级参考文献95
-
1高向阳,林碧润,姚汝华,谢双大,沈会芳,江学斌.新抗生素万隆霉素对黄瓜疫病菌抑菌形态学研究[J].华南农业大学学报,2004,25(4):27-29. 被引量：15
-
2李桂兰,苗贞智,李玉贤.抗肿瘤药白消安的合成[J].河南科学,1995,13(3):231-232. 被引量：2
-
3马金兰,汤致强,周立强,冯奉仪,孙燕,张和平.盐酸博安霉素临床药代动力学研究[J].中国新药杂志,1995,4(4):42-44. 被引量：4
-
4李丽,顾觉奋,吴梧桐.烯二炔类抗肿瘤抗生素单克隆抗体导向药物研究进展[J].药物生物技术,2005,12(4):275-277. 被引量：2
-
5高佃台,王海昕,徐传进,王洪刚.卡莫司汀的合成[J].齐鲁药事,2005,24(9):559-560. 被引量：2
-
6争光霉素协作组.平阳霉素治疗恶性肿瘤的临床疗效评价[J].中华肿瘤杂志,1979,1:172-174.
-
7Tas F.Derin D,Guney N,et al.Chemotherapy with pcgylated liposomal doxorubicin and cisplatin in recurrcnt platinum-scnsitivc epithclial ovarian cancer[J].Int J Clin Oncol,2008,13(4):330-334.
-
8Belanti C P.Recent updates in the clinical use of platinum compounds for the treatment of lung,brest,and genitourinary tumors and mycloma[J].Semin Oncol,2004,31(6Suppl 14):25-33.
-
9Emest W,Cheristen M G.Current Status of Platinum based Antitumor Drugs[J].Chem Rev,1999,99:2451-2466.
-
10Reedijk J,P H M.Cisplatin:synthesis,antitumour activity and mcchanism of action[J].Pharmaceutisch Weckblad Scientific Edition,1985.7:173-180.
共引文献25
-
1陈念,赵树进.喹喔啉类抗肿瘤抗生素研究进展[J].实用医学杂志,2006,22(21):2569-2570. 被引量：2
-
2Liang Li Yun-Hong Huang Yi Li Feng-Qiang Wang Bo-Yang Shang Yong-Su Zhen.Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma[J].World Journal of Gastroenterology,2005,11(29):4478-4483. 被引量：9
-
3陈念,高向阳,林壁润.万隆霉素抑制细菌的作用机理初探[J].西北农林科技大学学报（自然科学版）,2005,33(B08):143-147. 被引量：13
-
4宋波,戴垚,黎维勇,金文闻,陈华庭.蓖麻蛋白A链与单抗3G11偶联物的制备及体外生物活性研究[J].中国医院药学杂志,2005,25(10):899-901. 被引量：1
-
5戴垚,刘秀均,甄永苏.抗IV型胶原酶单抗与平阳霉素新型免疫偶联物的抗肿瘤作用[J].药学学报,2006,41(1):41-46. 被引量：16
-
6徐静,陈孝平.棘霉素诱导肝癌SMMC7721细胞凋亡的研究[J].山东医药,2007,47(15):14-16.
-
7封云,甄永苏,戴垚,尚伯杨,张敏,何红伟,李保卫,邵荣光.不同力达霉素与抗VI型胶原酶单抗偶联物的抗肿瘤作用[J].药学学报,2007,42(7):704-709. 被引量：8
-
8MIAO QingFang, SHANG BoYang, OUYANG ZhiGang, LIU XiaoYun & ZHEN YongSu Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin[J].Science China(Life Sciences),2007,50(4):447-456. 被引量：3
-
9封云,邵荣光,戴垚,李保卫,何红伟,任开环.力达霉素-单抗Fab＇片段不同连接偶联物的抗肿瘤作用比较[J].药学学报,2010,45(5):571-575. 被引量：6
-
10陈淑珍,甄永苏,邵荣光.力达霉素抗肿瘤作用及其分子机制研究新进展[J].中国抗生素杂志,2010,35(6):401-407. 被引量：8
同被引文献32
-
1袁捷,刘顺英.血管内皮细胞生长因子在胃癌外周血微转移中的作用[J].中华消化杂志,2005,25(10):629-630. 被引量：7
-
2王妍,韩燕星,蒋建东.刺孢霉素族抗生素的研究进展[J].中国新药杂志,2007,16(17):1341-1345. 被引量：4
-
3Galm U,Wendt PE, Wang L,et al. Comparative analysis of the biosyn- thetic gene clusters and pathways： for three structurally related antitumor antibiotics: bleomycin, tallysomycin, and zorbamycin [ J ]. J Nat Prod, 2011,74(3) :526 -536.
-
4Chen Y,Yin M, Horsman GP,et al. Improvement of the enediyne antitu- mot antibiotic C-1027 production by manipulating its biosynthetic path- way regulation in streptomyces globisporus [ J ]. J Nat Prod, 2011,74 (3) :420 -424.
-
5Usui N,Takeshita A, Nakaseko C, et al. Phase I trial of gemtuzumab ozo- gamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML) : Japan Adult Leukemia Study Group (JALSG)-AML 206 Study[J]. Cancer Sci,2011,102(7) :1358 - 1365.
-
6Jager E,Velden VH,Marvelde JG,et al. Targeted drug delivery by gem- tuzumab ozogamicin: mechanism-based mathematical model for treat- ment strategy improvement and therapy individualization [ J ]. Cancer Sci,2011,6(9) :24265 -24275.
-
7Dijoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activi- ty of antibody-targeted chemotherapy with CMC-544 ( inotuzumab ozo- gamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP [ J]. Cancer Chemother Pharmacol,2011,67 (4) :741 - 749.
-
8Ognra M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozo- gamicin (CMC-544)in japanese patients with follicular lymphoma pre- treated with rituximab-based therapy [ J ]. Cancer Sci, 2010,101 ( 8 ) : 1840 - 1845.
-
9Takeshita A, Yamakage N, Shinjo K,et al. CMC-544 ( inotuzumab ozo- gamicin) ,an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells [ J ]. Leukemia, 2009,23 (7) :1329 - 1336.
-
10Kelly MP, Lee K, Power BE, et al. Tumor targeting by a multivalent sin- gle-chain fvcsfv antilewis tantibody construct [ J ]. Cancer Biotherapy- anp ; Radio Pharmaceuticals,2008,23 (4) :411 - 423.
引证文献4
-
1李标,林伟民,田树红,李凡,李富.科罗索酸的抗肿瘤作用及其对CAM和YSM血管生成的影响[J].中国生化药物杂志,2014,34(4):21-23. 被引量：2
-
2张庆娟.烯二炔类抗肿瘤抗生素卡利奇霉素的研究进展[J].临床合理用药杂志,2013,6(28):177-178.
-
3彭苗苗,方芸,刘慧.2011～2013年南京市样本医院抗肿瘤抗生素应用现状和趋势分析[J].药学与临床研究,2014,22(6):566-568.
-
4杨本官,隋华芹,马庆文,潘绍云.蒽环类药物盐酸表柔比星专利保护启示[J].中国发明与专利,2018,15(7):60-65.
-
1许鸿章,陈汝贤,张瑞,鲁敏.肿瘤抗生素在治疗银屑病及脂溢性皮炎中的新用途[J].科技开发动态,2004(6):36-36.
-
2邵荣光,甄永苏.烯二炔类高效抗肿瘤抗生素研究进展[J].国外医药（抗生素分册）,1995,16(3):194-199. 被引量：4
-
3邓卫燕.我院2008～2011年抗菌药物的不良反应分析[J].中国当代医药,2011,18(35):161-162. 被引量：5
-
4柯伟民.几类抗菌药物的临床应用概况[J].国外医学（流行病学．传染病学分册）,1996,23(3):97-101.
-
5许铁男.抗生素Clarithromycin[J].国外医药（合成药．生化药．制剂分册）,1992,13(5):307-308.
-
6王庆娥,王来成,韩强,胡丽丽.头孢曲松与其他药物联合用药实例分析[J].齐齐哈尔医学院学报,2010,31(23):3732-3734. 被引量：7
-
7李裴裴.住院患者抗菌药物使用情况调查分析[J].临床医药文献电子杂志,2016,3(53):10643-10643.
-
8郭和清.FK506的潜能与毒性[J].解放军医学情报,1993,7(2):80-83.
-
9何林,杜淑贤.克拉霉素的临床应用评价[J].华西药学杂志,2004,19(6):486-488. 被引量：7
-
10于福文,李娜,王冰晖.从抗生素后效应谈临床用药[J].中国临床药学杂志,2001,10(4):258-260. 被引量：7
